Allergan again rebuffed advances from Valeant Pharmaceuticals, saying that its board has unanimously determined that the unsolicited exchange offer to buy the Botox maker is "grossly inadequate."
via WSJ.com: US Business http://ift.tt/1p9UKJt
via WSJ.com: US Business http://ift.tt/1p9UKJt
Nessun commento:
Posta un commento